Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Jamjoom Pharmaceuticals Factory Company SJSC
Jamjoom Pharma makes and sells medicines and consumer health products, mostly branded generics, across Saudi Arabia and the wider Middle East and North Africa.
Jamjoom Pharma is a Saudi drugmaker. It makes medicines and consumer health products — things like eye drops, creams, syrups, and everyday treatments — and sells them under its own brands to pharmacies, hospitals, and distributors. Most of its business is in Saudi Arabia, but it also sells across the Gulf, Iraq, Egypt, and North Africa, and it has been pushing into international markets.
The core of the business is what the industry calls branded generics. These are medicines whose patents have expired, so anyone can make them, but Jamjoom sells them under its own name and builds trust with doctors and pharmacists. That matters in this region: customers and prescribers often prefer a familiar brand over an unbranded pill, even when the chemical inside is the same. Jamjoom's biggest strength is its ophthalmology line — eye-care products are a large and profitable part of its sales — plus a broad shelf of dermatology and other treatments. The money comes from selling those products at a markup over what it costs to make them. Jamjoom runs its own manufacturing plants, which lets it control quality and cost, and it invests in marketing to keep its brands in front of prescribers. The pitch to customers is simple: reliable, locally made medicines at prices below what the big global drugmakers charge for their branded versions. It competes with those multinationals as well as with other regional generic makers, and it benefits from a Saudi push to grow local manufacturing.
The company listed on the Saudi stock exchange in 2023, and it has been growing fast, with revenue climbing sharply in recent years as it expands into new countries and new product lines. A big part of the story is simply geography: Saudi Arabia's population is young and growing, healthcare spending is rising, and governments in the region want more medicines made at home. That tailwind is real, but it cuts both ways — price pressure from health authorities and currency swings in places like Egypt can squeeze margins. Jamjoom's bet is that a trusted local brand plus its own factories is a durable edge. So far, the numbers have backed that up.
Saved answer · last researched 12 Nov 2026